AU2023205152A1 - Methods of treating or reducing risk of transplant rejection - Google Patents

Methods of treating or reducing risk of transplant rejection Download PDF

Info

Publication number
AU2023205152A1
AU2023205152A1 AU2023205152A AU2023205152A AU2023205152A1 AU 2023205152 A1 AU2023205152 A1 AU 2023205152A1 AU 2023205152 A AU2023205152 A AU 2023205152A AU 2023205152 A AU2023205152 A AU 2023205152A AU 2023205152 A1 AU2023205152 A1 AU 2023205152A1
Authority
AU
Australia
Prior art keywords
transplant
days
administered
hours
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023205152A
Other languages
English (en)
Inventor
Muhammad M. MOHIUDDIN
John F. Paolini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiniksa Pharmaceuticals GmbH
University of Maryland Baltimore
Original Assignee
Kiniksa Pharmaceuticals GmbH
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals GmbH, University of Maryland Baltimore, University of Maryland College Park filed Critical Kiniksa Pharmaceuticals GmbH
Publication of AU2023205152A1 publication Critical patent/AU2023205152A1/en
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, KINIKSA PHARMACEUTICALS, GMBH reassignment UNIVERSITY OF MARYLAND, BALTIMORE Request for Assignment Assignors: KINIKSA PHARMACEUTICALS, LTD., UNIVERSITY OF MARYLAND, BALTIMORE
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2023205152A 2022-01-10 2023-01-10 Methods of treating or reducing risk of transplant rejection Pending AU2023205152A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263298133P 2022-01-10 2022-01-10
US63/298,133 2022-01-10
US202263307911P 2022-02-08 2022-02-08
US63/307,911 2022-02-08
US202263327986P 2022-04-06 2022-04-06
US63/327,986 2022-04-06
PCT/US2023/060358 WO2023133577A1 (en) 2022-01-10 2023-01-10 Methods of treating or reducing risk of transplant rejection

Publications (1)

Publication Number Publication Date
AU2023205152A1 true AU2023205152A1 (en) 2024-07-18

Family

ID=87074361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023205152A Pending AU2023205152A1 (en) 2022-01-10 2023-01-10 Methods of treating or reducing risk of transplant rejection

Country Status (8)

Country Link
US (1) US20230287132A1 (https=)
EP (1) EP4463182A1 (https=)
JP (1) JP2025502095A (https=)
KR (1) KR20240131437A (https=)
AU (1) AU2023205152A1 (https=)
CA (1) CA3242941A1 (https=)
MX (1) MX2024008562A (https=)
WO (1) WO2023133577A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
WO2017040932A1 (en) * 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2023133577A1 (en) 2023-07-13
KR20240131437A (ko) 2024-08-30
JP2025502095A (ja) 2025-01-24
MX2024008562A (es) 2024-12-06
US20230287132A1 (en) 2023-09-14
CA3242941A1 (en) 2023-07-13
EP4463182A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
US20230287132A1 (en) Methods of treating or reducing risk of transplant rejection
US12240894B2 (en) Methods of treating AL amyloidosis
CN119405797A (zh) 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
TW202417482A (zh) 治療補體介導疾病的方法
US20240052062A1 (en) Reducing surgery-associated hemolysis in cold agglutinin disease patients
JP2020517605A (ja) 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性
CN116783216A (zh) 用于诱导耐受性的方法和组合物
US20250084153A1 (en) Methods of treating al amyloidosis
CN118891285A (zh) 治疗移植物排斥或降低移植物排斥风险的方法
WO2021052472A1 (zh) 抗pcsk9抗体用于预防或治疗胆固醇相关疾病的方法
US20250345418A1 (en) Methods of treating al amyloidosis
TWI870415B (zh) 使用抗cd38抗體之組合療法
TW202606724A (zh) 器官移植中缺血再灌注損傷之治療或預防
JP2025532869A (ja) 慢性腎疾患を有する患者における心臓手術関連急性腎損傷（ｃｓａ－ａｋｉ）及び／又はその後の主要な腎臓有害事象（ｍａｋｅ）を予防又は最小化するための抗ｃ５抗体の投薬及び投与
JP2025126668A (ja) 人免疫グロブリンｇを有効成分として含有する、腎臓移植後の抗体関連型拒絶反応の治療剤
TW202547553A (zh) 治療ａｌ類澱粉變性症之方法
WO2023107100A1 (en) Methods and treatment for multiple myeloma involving antibodies to il-18
AU2020339737A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF MARYLAND, BALTIMORE

Free format text: FORMER APPLICANT(S): KINIKSA PHARMACEUTICALS, LTD.; UNIVERSITY OF MARYLAND, BALTIMORE

Owner name: KINIKSA PHARMACEUTICALS, GMBH

Free format text: FORMER APPLICANT(S): KINIKSA PHARMACEUTICALS, LTD.; UNIVERSITY OF MARYLAND, BALTIMORE